Daniel James George, MD

Professor of Medicine
Professor in Surgery
Member of the Duke Cancer Institute
Campus mail Duke Box 103861, Durham, NC 27710
Phone (919) 668-4615
Email address daniel.george@duke.edu

Education and Training

  • Fellow in Medical Oncology, Medicine, Johns Hopkins University, 1995 - 1998
  • Medical Resident, Medicine, Johns Hopkins University, 1992 - 1995
  • M.D., Duke University, 1992

Grants

Publications

Battle, Dena, Eric Jonasch, Hans J. Hammers, Ithaar Derweesh, Daniel J. George, Axel Bex, Borje Ljungberg, and Michael D. Staehler. “Patients perspectives on adjuvant therapy in renal cell carcinoma.” In Journal of Clinical Oncology, 36:644–644. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.6_suppl.644.

Full Text

George, Daniel J., Allan J. Pantuck, Robert J. Motzer, Alain Ravaud, Bernard Escudier, Michael D. Staehler, Lucile Serfass, et al. “S-TRAC trial: Sensitivity analyses of disease-free survival (DFS).” In Journal of Clinical Oncology, 36:633–633. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.6_suppl.633.

Full Text

Clarke, Jeffrey M., Daniel J. George, Stacey Lisi, and April K. S. Salama. “Immune Checkpoint Blockade: The New Frontier in Cancer Treatment.” Target Oncol 13, no. 1 (February 2018): 1–20. https://doi.org/10.1007/s11523-017-0549-7.

PMID
29441437
Full Text

Ramalingam, Sundhar, Daniel J. George, and Michael R. Harrison. “How we treat brain metastases in metastatic renal cell carcinoma.” Clin Adv Hematol Oncol 16, no. 2 (February 2018): 110–14.

PMID
29741510
Scholars@Duke

Koshkin, Vadim S., Pedro C. Barata, Tian Zhang, Daniel J. George, Michael B. Atkins, William J. Kelly, Nicholas J. Vogelzang, et al. “Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.” J Immunother Cancer 6, no. 1 (January 29, 2018): 9. https://doi.org/10.1186/s40425-018-0319-9.

PMID
29378660
Full Text

Zhu, Jason, Andrew J. Armstrong, Terence W. Friedlander, Won Kim, Sumanta K. Pal, Daniel J. George, and Tian Zhang. “Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.” J Immunother Cancer 6, no. 1 (January 25, 2018): 4. https://doi.org/10.1186/s40425-018-0314-1.

PMID
29368638
Full Text

Carlo, Maria I., Veda N. Giri, Channing J. Paller, Wassim Abida, Joshi J. Alumkal, Tomasz M. Beer, Himisha Beltran, et al. “Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.” Jco Precis Oncol 2018 (2018). https://doi.org/10.1200/PO.18.00060.

PMID
30761386
Full Text

Armstrong, A. J., E. S. Antonarakis, M. -. E. Taplin, W. K. Kelly, H. Beltran, K. Fizazi, W. L. Dahut, et al. “Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet.” Ann Oncol 29, no. 1 (January 1, 2018): 23–25. https://doi.org/10.1093/annonc/mdx648.

PMID
29088323
Full Text

Motzer, Robert J., Alain Ravaud, Jean-Jacques Patard, Hardev S. Pandha, Daniel J. George, Anup Patel, Yen-Hwa Chang, et al. “Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.” Eur Urol 73, no. 1 (January 2018): 62–68. https://doi.org/10.1016/j.eururo.2017.09.008.

PMID
28967554
Full Text

Zhu, Jason, Matthew Tucker, Endi Wang, Joel S. Grossman, Andrew J. Armstrong, Daniel J. George, and Tian Zhang. “Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer.” Clin Genitourin Cancer 15, no. 6 (December 2017): e1137–41. https://doi.org/10.1016/j.clgc.2017.07.005.

PMID
28780018
Full Text

Pages